Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109316 · ClinicalTrials.gov registry record · Phase 3
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
NCT01109316 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 132 participants.
The verdict
NCT01109316, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
Study Summary
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion \[CSII\]) compared to insulin aspart over 6 days of pump reservoir in-use. The study will also compare the in-use characteristics of insulin lispro infused at 6 days with insulin lispro infused at 2 days.
Interventions
- DRUG Insulin lispro 2 day reservoir in-use
- DRUG Insulin lispro 6 day reservoir in-use
- DRUG Insulin aspart 6 day reservoir in-use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01109316
The ClinicalTrials.gov registry entry for NCT01109316 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin lispro 2 day reservoir in-use is the first listed.
NCT01109316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01109316 about?
NCT01109316 is a clinical study titled "Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use". This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion \[CSII\]) compared to insulin aspart over 6 days of pump reservoir in-use. The st...
What is the current status of trial NCT01109316?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2010-04. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01109316?
The interventions under investigation include: Insulin lispro 2 day reservoir in-use (DRUG), Insulin lispro 6 day reservoir in-use (DRUG), Insulin aspart 6 day reservoir in-use (DRUG).
Who is sponsoring clinical trial NCT01109316?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.